Fluralaner Tablet: Broad-Spectrum Acaricide Explained

A health worry is definitely when your pet is continually scratching or if you find a tick implanted deep in its skin. Fleas, ticks and mites are external parasites that are more than just a nuisance – they cause disease, allergic reactions and reduce the quality of life for companion animals. Lately, fluralaner tablet has been developed as one of the most reliable systemic options in contemporary veterinary parasitology, providing prolonged, wide-ranging protection after a single oral dose. What's it do? How does it do it? And why do vets and pet owners throughout the globe trust it? This article breaks it all down.

Fluralaner Tablet

1.General Specification(in stock)
(1)Solution
(2)Tablet
(3)Injection
(4)Spray
(5)Drops
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code:BM-2-079
Fluralaner CAS 864731-61-3
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory

A Novel Chemical Class With a Precise Target

Fluralaner tablet is an isoxazoline chemical class substance that is designed to interfere with invertebrate brain signaling. "Unlike previous pesticides that have extensive interactions with mammalian and insect physiology, fluralaner targets ion channel proteins that are physically different in arthropods. This selectivity is not an accident, but a manifestation of purposeful chemical design that increases parasiticidal effectiveness while retaining a wide safety buffer in dogs and cats.

Published studies in veterinary pharmacology journals demonstrate fluralaner reaches maximal plasma concentration within hours of oral treatment, and systemic distribution maintains therapeutic levels active for up to 12 weeks in dogs and 12 weeks in cats.

That length of time counts: continual blood level control means each parasite that touches the host hits a deadly dose.

Speed of Kill and Coverage Range

Its speed separates fluralaner from several of its competitors. Clinical findings demonstrate that a single oral dose will remove more than 98% of the Ctenocephalides felis (cat flea) population within 12 hours and 100% within 48 hours. For ticks such as Ixodes scapularis, the principal vector for Lyme disease, efficacy is measurable within 8 hours of the parasite adhering to the host.

The scope extends considerably beyond fleas and ticks.

It also includes scabies mite (Sarcoptes scabiei), ear mites (Otodectes cynotis) and Demodex spp.Therefore, fluralaner tablet is a very broad spectrum acaricide that is in therapeutic use.

Blocking GABA and Glutamate-Gated Chloride Channels

Pharmacological activity of Fluralaner tablet is on two ion channel targets: gamma-aminobutyric acid (GABA)-gated chloride channels and glutamate-gated chloride channels. Both types of channels mediate neural inhibition in arthropods. The binding of fluralaner to these channels prevents chloride ions from entering the nerve cells, locking the nervous system of the insect or arachnid in a state of relentless excitation. The end effect is fast paralysis and then death.

That dual channel blocking is critical. Resistance to single target drugs has become a growing concern in veterinary parasitology. Fluralaner works through two parallel routes.

This mechanistic redundancy means that parasites have a tougher time escaping therapy by single-gene changes. 

Why Mammals Remain Unaffected

Any pet owner has a reasonable concern about drug safety. The mammalian GABA receptor is located in the central nervous system and is protected by the blood-brain barrier. At therapeutic concentrations, fluralaner does not overcome this barrier. The ion channel disruption which is fatal to fleas and ticks does not have any demonstrable neurological effect in dogs or cats. Strong safety data from many pre-clinical and clinical studies support regulatory approvals from authorities such as the US FDA and EU.

Comprehensive Flea Management Beyond Surface Treatment

Spot-on treatments do a good job of controlling the fleas that are around when applied, but they have holes. Fluralaner pill as a systemic drug is distributed in the blood stream and reaches to each parasitic organism feeding on the host, irrespective of coat density or washing habits. After delivery, fleas bite the victim and swallow a fatal amount through the blood meal itself. This method also lowers environmental contamination: by killing adult, reproducing fleas in a short time, the tablet addresses the flea life cycle at its source, therefore reducing the quantity of eggs and larvae laid in the house.

Another benefit of flea management in cats is the reduced risk of transfer of Bartonella henselae , the bacteria responsible for cat scratch disease in humans.

Tick Species Covered and Disease Prevention

Fluralaner tablets are effective against a significant spectrum of tick species in dogs and cats. Species covered by the compound include the Rocky Mountain spotted fever vector Dermacentor variabilis, the canine and feline babesia vector Rhipicephalus sanguineus, the Lyme borreliosis and anaplasmosis vector Ixodes scapularis and the emerging species with zoonotic potential, Haemaphysalis longicornis.

Fluralaner reduces the risk of pathogen transmission directly by shortening the period of tick attachment and increasing the kill speed.Many tick-borne infections require hours of attachment before transfer occurs.

Oral Absorption and Systemic Distribution

After a dog or cat has ingested a fluralaner pill, the active molecule is absorbed from the gastrointestinal tract into the blood circulation. Administration with food improves bioavailability resulting in more consistent systemic exposure. The chemical distributes to the tissues and is measurable in plasma at therapeutically relevant quantities for the entire dosage interval. This systemic residency is what allows one tablet to last for weeks of continuous protection.

How Parasites Encounter the Drug

Fleas, ticks and mites do not absorb fluralaner via contact with the environment – they experience it through blood meal. With a flea bite on a treated pet, the flea consumes blood containing the active component, which quickly interferes with its neurological system. This approach bypasses the necessity for direct contact between the medicine and the parasite on the skin surface, a restriction of many topical formulations, particularly in animals with thick undercoats or who are constantly exposed to water.

Single-Dose Convenience With Extended Duration

Consistent veterinary compliance data indicate that owners tolerate oral treatments with longer dose intervals better than monthly topical treatments. Fluralaner pill offers up to 12 weeks proven duration of effect, resulting in fewer missed doses and a more consistent level of parasite control throughout time. For working animals - guiding dogs, search and rescue dogs, hunting dogs – continuous protection is a professional need, not a preference.

Evidence-Based Efficacy Across Multiple Indications

Clinical evidence supports the use of the fluralaner pill for flea allergic dermatitis, sarcoptic mange, demodicosis, otoacariasis due to ear mites and multi-species tick infestation. In sarcoptic mange, a single dose reduced pruritus scores by 80% in two weeks and resulted in 95% recovery by four weeks. Ear mite infections were cured with greater than 90% of the mites killed within 72 hours and a 100% cure rate after 14 days. These numbers are from controlled veterinary studies, not anecdotal tales.

Safety Profile and Regulatory Standing

Fluralaner has been reviewed for safety and efficacy by various regulatory agencies including the US FDA,

EU European Medicines Agency framework and Japan's PMDA.The chemical has an established tolerability profile in healthy adult dogs and cats. Veterinarians in markets spanning North America to Southeast Asia and Europe are prescribing it with confidence, supported by a robust corpus of peer-reviewed pharmacovigilance data.

Fluralaner tablet joins the broad spectrum acaricide class with a unique mix of accurate dual ion-channel activity, systemic distribution, high speed of kill and long dosing interval to promote real-world compliance. With a broad spectrum of activity against flea allergic dermatitis, multi-species tick exposure or mite infestations, the chemical covers the whole range of external parasite issues dogs and cats face. Its safety profile is supported by assessment by global regulators and makes it eligible for routine veterinarian prescription across a diverse set of regional markets. "Manufacturers, distributors and research institutions seeking a dependable supply partner will discover that Bloomtechz possesses the quality infrastructure and technical capability to satisfy these needs at scale."

Bloomtechz has over 12 years experience in the production of organic chemical synthesis and pharmaceutical intermediates and is a GMP certified manufacturer and confirmed supplier of fluralaner tablets. Our 100,000 sq.m facility in Xi'an is US FDA, EU GMP, JP and CFDA certified, and we have 3 independent verification stages of quality assurance before any product leaves the plant. We have 24 qualified international customers in the pharmaceutical, research & veterinary health sectors. We offer OEM and ODM, flexible formulation formats such as tablets, solutions, injections, sprays and drops, and transparent pricing with fixed margin structures for long-term partnership.

Whether you need bulk fluralaner tablet for veterinary distribution or unique formulations for scientific study, Bloomtechz offers precise lead times, complete documentation for customs clearance and a specialized technical support staff from our R&D department.

Reach out today: Sales@bloomtechz.com

1. Taenzler, J., Liebenberg, J., Roepke, R. K. A., & Frénais, R. (2014). Efficacy of fluralaner administered either orally or topically for the treatment of naturally acquired Sarcoptes scabiei var. canis infestations in dogs. Parasites & Vectors, 7, 595.

2. Kilp, S., Ramirez, D., Allan, M. J., & Roepke, R. K. A. (2014). Pharmacokinetics of fluralaner in dogs following a single oral or intravenous administration. Parasites & Vectors, 7, 85.

3. Fourie, J. J., Liebenberg, J. E., Horak, I. G., Taenzler, J., Heckeroth, A. R., & Frénais, R. (2013). Efficacy of orally administered fluralaner (Bravecto™) or topically applied imidacloprid/moxidectin against generalized demodicosis in dogs. Parasites & Vectors, 6, 187.

4. Dryden, M. W., Smith, V., Bennett, G., Math, L., & Sun, F. (2013). Evaluation of fluralaner topical solution and oral tablet for flea control in naturally infested cats and dogs in private residences. Veterinary Parasitology, 193(1–3), 55–61.

5. European Medicines Agency. (2014). Assessment report: Bravecto (fluralaner). Committee for Medicinal Products for Veterinary Use (CVMP), EMA/CVMP/659921/2013.

6. Rohdich, N., Roepke, R. K. A., & Zschiesche, E. (2014). A randomized, blinded, controlled and multi-centered field study comparing the efficacy and safety of Bravecto (fluralaner) against Frontline (fipronil) in flea- and tick-infested dogs. Parasites & Vectors, 7, 83.